Interaksi Glimepirid dan Linagliptin

Glimepirid dan Linagliptin: kedua label peresepan menguraikan interaksi yang biasanya memerlukan pemantauan, perubahan dosis, atau pemberian jarak antardosis.

Moderat

Biasanya dapat dikelola dengan pemantauan atau perubahan dosis. Beri tahu apoteker Anda bahwa Anda menggunakan keduanya.

Apa kata label FDA

Dari label Glimepirid (Glimepiride) · berlaku sejak 2026-05-06

Moderat

• Macrovascular Outcomes: No clinical studies establishing conclusive evidence of macrovascular risk reduction with glimepiride tablets or any other antidiabetic drug.

Peringatan dan perhatianberdasarkan golongan obatLihat label di DailyMed
Moderat

Although only one drug in the sulfonylurea class (tolbutamide) was included in this study, it is prudent from a safety standpoint to consider that this warning may also apply to other oral hypoglycemic drugs in this class, in view of their close similarities in mode of action and chemical structure.

Peringatan dan perhatianberdasarkan golongan obatLihat label di DailyMed
Moderat

The following are examples of medications that may increase the glucose-lowering effect of sulfonylureas including glimepiride, increasing the susceptibility to and/or intensity of hypoglycemia: oral anti-diabetic medications, pramlintide acetate, insulin, angiotensin converting enzyme (ACE) inhibitors, H 2 receptor antagonists, fibrates, propoxyphene, pentoxifylline,…

Interaksi obatberdasarkan golongan obatLihat label di DailyMed
Moderat

The following are examples of medications that may reduce the glucose-lowering effect of sulfonylureas including glimepiride, leading to worsening glycemic control: danazol, glucagon, somatropin, protease inhibitors, atypical antipsychotic medications (e.g., olanzapine and clozapine), barbiturates, diazoxide, laxatives, rifampin, thiazides and other diuretics,…

Interaksi obatberdasarkan golongan obatLihat label di DailyMed
Moderat

Both acute and chronic alcohol intake may potentiate or weaken the glucose-lowering action of glimepiride in an unpredictable fashion.

Interaksi obatberdasarkan golongan obatLihat label di DailyMed

Dari label Linagliptin (Tradjenta) · berlaku sejak 2025-03-21

Moderat

Hypoglycemia: Consider lowering the dosage of insulin secretagogue or insulin to reduce the risk of hypoglycemia when initiating TRADJENTA ( 5.2 )

Peringatan dan perhatianberdasarkan golongan obatLihat label di DailyMed
Moderat

Hypoglycemia with Concomitant Use with Insulin and Insulin Secretagogues Insulin secretagogues and insulin are known to cause hypoglycemia.

Peringatan dan perhatianberdasarkan golongan obatLihat label di DailyMed
Moderat

The risk of hypoglycemia is increased when TRADJENTA is used in combination with an insulin secretagogue (e.g., sulfonylurea) or insulin [see Adverse Reactions (6.1) ] .

Peringatan dan perhatianberdasarkan golongan obatLihat label di DailyMed
Moderat

Therefore, a lower dosage of the insulin secretagogue or insulin may be required to reduce the risk of hypoglycemia when used in combination with TRADJENTA.

Peringatan dan perhatianberdasarkan golongan obatLihat label di DailyMed
Moderat

Insulin Secretagogues or Insulin Insulin and insulin secretagogues are known to cause hypoglycemia.

Interaksi obatberdasarkan golongan obatLihat label di DailyMed

Menggunakan lebih dari dua obat ini? Interaksi saling bertumpuk. Periksa seluruh daftar Anda sekaligus; daftar itu tetap berada di peramban Anda.

Buka di pemeriksa

Bukan nasihat medis. Interaction Checker mengutip teks label FDA dan lembar fakta NIH. Penting atau tidaknya suatu interaksi bagi Anda bergantung pada dosis, waktu penggunaan, fungsi ginjal dan hati, serta kondisi lain. Pastikan dengan apoteker atau dokter yang meresepkan.